Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement - PubMed
5 hours ago
- #Immunotherapy
- #Amivantamab
- #Mesothelioma
- Amivantamab, a bispecific antibody targeting EGFR and MET, shows preclinical activity in diffuse pleural mesothelioma (DPM), a lethal cancer with no approved targeted therapies.
- Transcriptomic and immunohistochemical analyses confirm frequent co-expression of EGFR and MET in DPM patient samples and cell lines across histologic subtypes.
- In vitro, amivantamab binds to DPM cells, blocks EGFR and MET signaling, promotes receptor internalization, and induces NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).
- In vivo studies using mesothelioma patient-derived xenograft models demonstrate that amivantamab combined with human NK cells significantly reduces tumor growth without overt toxicity.
- The findings support clinical evaluation of bispecific EGFR/MET-targeting antibodies like amivantamab for mesothelioma treatment, primarily through innate immune-mediated cytotoxicity.